| Literature DB >> 24187620 |
Hongqi Ren1, Xuan Zhou, Zhiyong Luan, Xiaomei Luo, Shujing Han, Qing Cai, Wang Rui, Yan Li.
Abstract
Objective. To identify the relationship between microinflammation, oxidative stress, and carotid arterial stiffness in hemodialysis patients. Methods. The CAS β and PWV obtained by ultrasound technology were used to assess carotid arterial stiffness. We divided the patients into either the CAS group or the non-CAS group based on the presence or absence of CAS. The parameters of ALB, Ca, P, TC, HDL, LDL, TG, glucose, creatinine, and hs-CRP levels were routinely tested in both groups of patients. The levels of TNF- α , IL-6, and 8-isoprostane F2 α were measured by ELISA. Results. A total of 42 patients were enrolled in the CAS group and 20 patients were enrolled in the non-CAS group. No significant differences between the CAS group and the non-CAS group were observed with respect to age, dialysis duration, DBP, BUN, Cr, TC, TG, HDL, LDL, and Hb. However, SBP , pulse pressure, and 8-isoprostane levels of the CAS group were higher than those of the non-CAS group. The hs-CRP, TNF- α , and IL-6 levels were elevated in both groups but showed no significant differences. Conclusions. Maintenance of hemodialysis patients exhibits a microinflammatory state that may lead to atherosclerosis. The roles of hypertension and oxidative stress may be more important.Entities:
Year: 2013 PMID: 24187620 PMCID: PMC3800632 DOI: 10.1155/2013/835465
Source DB: PubMed Journal: Int J Nephrol
Basic conditions of the study groups.
| Control | Non-CAS | CAS | |
|---|---|---|---|
| Age (years) | 57.9 ± 7.8 | 56.6 ± 9.6 | 57.2 ± 7.8 |
|
| |||
| Gender (M/F) | 7/5 | 12/8 | 31/11 |
| Duration of dialysis (months) | / | 32 (3–56) | 34 (3–61) |
| SBP (mmHg) | 131.08 ± 7.66 | 137.27 ± 11.23* | 151.33 ± 13.57∗∗▲ |
| DBP (mmHg) | 72.66 ± 9.62 | 83.25 ± 10.48* | 81.62 ± 11.35* |
| Pulse pressure (mmHg) | 47.21 ± 8.37 | 56.96 ± 6.18 | 67.26 ± 18.22∗∗▲ |
| BUN (mmol/L) | 5.13 ± 0.69 | 23.36 ± 10.34** | 23.31 ± 8.49** |
| Scr ( | 62.58 ± 13.29 | 756.6 ± 131.8** | 862.1 ± 157.4** |
| Hb (g/L) | 14.33 ± 1.30 | 86.4 ± 24.6** | 80.3 ± 25.5** |
| TC (mmol/L) | 4.22 ± 0.61 | 4.26 ± 1.38 | 4.32 ± 1.22 |
| TG (mmol/L) | 1.74 ± 0.29 | 1.27 ± 0.37 | 1.32 ± 0.84 |
| HDL-c (mmol/L) | 1.37 ± 0.26 | 1.34 ± 0.23 | 1.27 ± 0.33 |
| LDL-c (mmol/L) | 2.49 ± 0.73 | 2.52 ± 0.84 | 2.43 ± 0.61 |
*P < 0.05 versus control; **P < 0.01 versus control; ▲ P < 0.05 versus non-CAS.
Comparisons of CAS indicators in the study groups.
| Control | Non-CAS | CAS | |
|---|---|---|---|
|
| 7.18 ± 2.12 | 7.38 ± 2.84 | 12.14 ± 6.21∗∗▲ |
| PWV | 5.93 ± 0.52 | 6.26 ± 0.62 | 7.52 ± 0.51∗∗▲ |
**P < 0.01 versus control; ▲ P < 0.05 versus non-CAS.
Comparisons of serum TNF-α, IL-6, and 8-isoprostane F2α concentrations in the study groups.
| Control | Non-CAS | CAS | |
|---|---|---|---|
| TNF- | 34.83 ± 10.46 | 83.67 ± 23.626* | 79.4 ± 21.57* |
| IL-6 (pg/mL) | 42.18 ± 13.47 | 128.36 ± 33.24* | 119.56 ± 25.62* |
| hs-CRP (mg/L) | 1.58 ± 0.79 | 7.54 ± 6.51* | 8.21 ± 7.63* |
| 8-isoprostane F2 | 17.32 ± 7.47 | 25.56 ± 27.48* | 68.77 ± 45.96** |
*P < 0.05, non-CAS versus control and CAS versus control; **P < 0.01, non-CAS versus CAS.